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Abstract
When the individual outcomes within a composite outcome appear to have different treatment effects, either in magnitude
or direction, researchers may question the validity or appropriateness of using this composite outcome as a basis for
measuring overall treatment effect in a randomized controlled trial. The question remains as to how to distinguish random
variation in estimated treatment effects from important heterogeneity within a composite outcome. This paper suggests
there may be some utility in directly testing the assumption of homogeneity of treatment effect across the individual
outcomes within a composite outcome. We describe a treatment heterogeneity test for composite outcomes based on a
class of models used for the analysis of correlated data arising from the measurement of multiple outcomes for the same
individuals. Such a test may be useful in planning a trial with a primary composite outcome and at trial end with final
analysis and presentation. We demonstrate how to determine the statistical power to detect composite outcome treatment
heterogeneity using the POISE Trial data. Then we describe how this test may be incorporated into a presentation of trial
results with composite outcomes. We conclude that it may be informative for trialists to assess the consistency of treatment
effects across the individual outcomes within a composite outcome using a formalized methodology and the suggested
test represents one option.
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Introduction
It is common to use primary composite outcomes in trials
designed to test the effectiveness of new therapies in preventing or
treating disease. Trialists identify a list of outcomes to include in
this composite that are thought to share the same disease pathways
and therefore, should show similar treatment effects, at least in
direction [1–7]. This type of composite outcome then assumes
homogeneity of treatment effect for all outcomes included in it.
However, this assumption can be challenged at the end of the trial,
when there is visible variation in the treatment effects among these
individual outcomes. Currently there are few formal methods to
determine if such variation is due to chance alone, or represents
new, unanticipated information that should change how we
interpret the overall treatment effect in a trial. This determination
is critical as an unanticipated treatment difference between
outcomes may alter our assumptions about mechanisms of action
potentially for both the treatment and the disease process itself.
Without using a formal statistical method to determine if the
outcomes within a composite share a common treatment effect,
individual readers may come to different conclusions, based solely
on variation in judgment. Given the importance of determining if
a primary composite outcome can validly represent the overall
treatment effect of an intervention, perhaps a more objective
assessment should be used.
It is easier to interpret the treatment effect for a primary
outcome where there is little variation in this effect for its
individual outcomes. The question remains open as to how
consistent these individual treatment effects need to be before we
should be concerned about using a primary composite outcome to
summarize the overall treatment effect. It has been suggested that
we may only accept the overall treatment effect if at least one
individual outcome also show statistically significant benefit [8].
Another view indicates that all individual outcomes contained in
the composite should have point estimates trending in the
direction of benefit [9,10]. Yet we know that power for these
individual outcome comparisons will be low in a trial designed to
have good power only for the primary composite outcome.
Random variation alone can easily result in variation in treatment
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powered subgroup analyses[11,12].
Ferreira-Ganzalez et al.[2] suggest using a gradient of efficacy
across the individual outcomes for a composite. This gradient is
defined as the difference between smallest and largest individual
outcome treatment effects, and these differences are then
organized into small, moderate or large categories. The limitation
of this method is that it does not take variability or the amount of
information into account, so can not distinguish random variation
from systematic differences.
We suggest that a composite outcome treatment heterogeneity
test can be used to clarify variation in treatment effect for the
individual outcomes with that composite. A heterogeneity or
interaction test is routinely used in both meta-analysis[13] and
subgroup[11,12] analysis to distinguish random variation from
systematic differences, and this determination is wisely based on
the amount of information available in the analysis. However, with
multiple outcomes recorded for the same trial participants, one
cannot merely use a simple Cochran’s Q test to detect differences
in treatment effect across outcomes. The individual outcomes
within a composite are correlated with one another and we need to
use statistical models that account for this correlation. The purpose
of this paper is to illustrate the use of appropriate statistical
methods to assess treatment heterogeneity in both the design and
analysis of a trial that uses a composite outcome.
Sometimes composite outcomes are formed to quantify risk-
benefit or capture competing risks. In these cases, there is no
expectation that the treatment will have the same effect on each
outcome within the composite. In fact, often it is expected that a
new therapy may have greater efficacy and greater harm, than a
standard one. In such a case, there is no assumption of
homogeneity of treatment effects across the composite components
and the methods proposed in this article would not be appropriate.
To illustrate this methodology we use the composite outcome
from the POISE Trial [14] as an example. Given our a priori
assumption that all components of this composite outcome would
share the same direction and approximate magnitude of treatment
effect, we present a statistical analysis to address the possible
contradiction of this assumption in the design and analysis stages.
Methods
The POISE trial [14] examined the effect of peri-operative
beta-blocker versus placebo in participants at risk of cardiovascular
events who were undergoing non-cardiac surgery. 8351 partici-
pants were randomized from 190 centers in 23 countries. The
primary composite outcome was time to first occurrence of non-
fatal myocardial infarction, non-fatal cardiac arrest, or cardiovas-
cular death within 30 days from randomization. The primary
analysis used a Cox regression for the treatment comparison of
time to first composite outcome. Results, published previously
[14], visually display a lack of homogeneity of treatment effect
across the components of the composite outcome (see figure 1).
We would like to fit the following general model:
fY ijk

~mzajzbz ab ðÞ jkzv 
For the ith patient, all outcome types included in the composite
outcome are analyzed in a single regression. A function (f) of the
outcome for each component of the composite Yijk, is estimated
from the following terms: aj represents the treatment effect for j
treatment groups, bk is the effect of each individual outcome of the
composite outcome for k individual outcome components, (ab)jk is
the interaction of treatment and individual outcomes, intercept m,
and v* is an error term whose structure will depend on the exact
model used. The test of whether the interaction term (ab)jk is
different from zero is the test of homogeneity of treatment effect
across the individual components of the composite outcome.
A trial where multiple outcomes are evaluated for the same
participants can be viewed as a repeated measures design. These
models include terms to account for the non-independence of
these data due to an association or correlation of the multiple
outcomes (i.e. components of a composite outcome) within a
participant. Regardless of the outcome type (binary, continuous, or
time to event) there are generally two statistical models used for
this type of analysis: random effects and marginal models. For
random effects, also known as mixed models, a term for individual
variation is incorporated in the model, usually to allow the slope of
the regression to vary across participants. Individuals are
considered to be randomly selected from a population with an
intercept assumed to follow a known distribution [15]. For the
current case this model would include a random intercept term ci
assumed to vary for each patient from a common statistical
distribution and an error term eijk:
fY ijk

~mzajzbkz ab ðÞ jkzcizeijk
For the marginal or population-averaged model, the association
of multiple outcomes within an individual is treated as a nuisance
factor and treatment effects are then estimated by averaging over
the variability due to the individual, or are obtained at the margin
[16]. Thus, the expectation of Yijk is modeled as follows:
fEY ijk
 
~m za 
j zb
 
kz ab ðÞ
 
jkze 
ijk
The coefficients from these two models have different
interpretations. The marginal model, the * indicates that the
coefficients are averaged effects, while the random effects model
produces effects specific to the individuals in the analysis.
Statistical models such as these may be used for many different
types of composite outcomes. A composite outcome may be
formed from a number of continuous outcomes, such as multiple
0.5 1.0 1.5 2.0 2.5
HR
Treatment
Benefit
Treatment
Harm
Primary Composite:
CV Death/MI/CA
CV Death
MI
Cardiac Arrest
HR (95% CI)
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0.70 (0.57-0.86)
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Figure 1. POISE [14] results for the primary composite outcome
and individual component outcomes. Hazard ratios and 95%
confidence interval for time-to-first composite outcome and for each
individual outcome within this composite.
doi:10.1371/journal.pone.0034785.g001
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continuous and normally-distributed composite outcomes, f()
would be the identity link and both marginal and random effects
models would be multivariate linear models of the types commonly
used for analysis of repeated observation on the same individu-
als[18]. For the case of a binary composite outcome, f() would be
the logit function for a logistic regression. This generalized linear
model for binary outcomes analyzes the probability of occurrence
of the different outcome types, the effect of treatment, and their
interaction on the logit scale. This interaction term would form the
composite outcome treatment heterogeneity test. For binary
composite outcomes, we have previously demonstrated that a
marginal logistic regression model using generalized estimating
equations [GEE] [16] had the greatest power to detect composite
treatment heterogeneity [19], compared to the random effects
model [15], and the weighted logistic regression model, weighted
by either the intra-class correlation coefficient [20] or equivalently
the variance inflation factor [21]. For time to event data, either the
random effects frailty models [22] or marginal models such as that
proposed by Wei, Lin and Weissfeld [23,24] may be used to
analyze multiple event time data. Both frailty models and marginal
models have been shown to be useful in detecting treatment
heterogeneity between the individual outcomes within a composite
outcome [25].
Using such a model for repeated or correlated outcome data, we
can calculate the power to detect possible heterogeneity of
treatment effect across the individual outcomes of the composite
outcome at the design stage of a trial. For example, for a time to
event composite outcome, we begin with estimated associations
between outcome survival times, and then simulate correlated
outcome data in order to calculate our chances of detecting a
different treatment effect for one individual outcome within the
composite outcome. Estimates of the association in survival times
for individual outcomes may be taken from existing trials or
databases of similar trial participants. Simple correlated time-to-
event data may be simulated by creating a Cox proportional
hazards model [26] that contains a random frailty term sampled
from an assumed distribution (e.g. gamma) to represent the
association between two survival times within an individual [22].
However, for greater than two outcomes with different associa-
tions between them, simulation of multivariate survival data may
be best done through the marginal model. Lin and Wei [23,24,27]
in developing a marginal model for multivariate time-to-event
data, assumed the regression coefficients followed an approxi-
mately multivariate normal distribution and then derived a
‘‘working’’ correlation matrix to adjust the covariance matrix
estimates for correlated data. The results are known as a
‘‘sandwich’’ estimator or ‘‘robust’’ covariance matrix. Using an
estimated robust covariance matrix from a prior dataset and
assuming normality of the regression parameters, one can sample
from this multivariate normal distribution and insert these within
the Cox proportional hazards model [26] to generate random
multivariate time-to-event data, provided that the estimated
covariance matrix is positive-semi definite [25].
Suppose we were to design a two-group trial in a similar
population to the POISE trial [14] with the same composite
outcome of first occurrence of non-fatal myocardial infarction,
non-fatal cardiac arrest, or cardiovascular death within 30 days
from randomization. Assume that during the study, myocardial
infarction (MI), cardiac arrest, and cardiovascular death will be
experienced by 6%, 0.5%, and 1.5% of the control group
participants, respectively. Also we assumed a further 1% of
individual will die of a non-cardiovascular cause. From POISE
[14] data, we could fit a marginal model to obtain an estimate of
the covariance matrix, adjusted for multiple outcomes per
participant. For the ith person, kth outcome type, and jth
treatment group, this model would include time to event for each
of the three outcomes per person (T1i,T 2i,T 3i) and three
classification variables (Y1i,Y 2i,Y 3i), indicating whether each Tik
represents an occurrence of the respective event time or a
censoring time due to end of follow-up. Covariates in this
regression would include treatment group [Gj=0 (control) or 1
(active)] and variables that compare the different outcomes to one
another [O1=0(MI) or 1(cardiovascular death), O2=0(MI) or
1(cardiac arrest)]. The following proportional hazards model
would be fit:
hijk t ðÞ ~h0 t ðÞexp b1Gjzb2O1zb3O2zb4 GjO1

zb5 GjO2
 
In this model, h0(t) represent the risk or hazard of having an MI
in the control group. The estimate of b1 represents the treatment
effect on the MI outcome, while b2 and b3 represent the difference
in risk or hazard between cardiovascular death and MI, and
cardiac arrest and MI, respectively. The interaction term b4
estimates the difference in treatment effect between cardiovascular
death and MI, and lastly, the interaction term b5 compares the
difference in treatment effect between cardiac arrest and MI. A
treatment heterogeneity test for the composite outcome would test
whether there are any significant differences between the three
individual outcomes in their treatment effect (testing the
hypothesis that b4=b5=0).
Given a robust estimated covariance matrix S and estimates of
h0(t), b2, b3 from POISE [14], we can assume a common
treatment effect or hazard ratio (l) for all three outcomes, and set
b1=ln(l), b4=0, and b5=0. We can then vary the effect on a
single interaction term (e.g. b4.0) to see what degree of
heterogeneity we may have reasonable power to detect in our
future trial. Given these estimates, we assumed that b1, b2, b3, b4,
and b5 were multivariate normal with estimated robust covariance
S (see table 1) and drew random samples of size 8,200 (4100 active
and 4100 control participants) from this multivariate distribution
to represent simulated participants in our new trial.
Assuming a constant baseline hazard h0(t) which followed an
exponential distribution, we used these randomly sampled
coefficients in the above Cox regression to generate survival times
(T1i,T 2i,T 3i) and classification variables (Y1i,Y 2i,Y 3i) for each
simulated participant. Censoring due to non-cardiovascular death
was also assumed to follow an exponential distribution. Power was
assessed as the number of simulations where a significant
treatment heterogeneity test was found, divided by the total
number of simulations. For the first series of simulations, the
treatment effect for MI and cardiac arrest were kept constant at a
hazard ratio of 0.70 while varying the treatment hazard ratio on
cardiovascular death from 0.70 to 2.0. Clear treatment homoge-
neity within the composite outcome occurs when all outcomes
have the same hazard ratio, and heterogeneity is observed to
greater degrees as the hazard ratio of one outcome increases. Each
of multiple simulated datasets were then be analyzed to determine
the chance of detecting statistically significant composite treatment
heterogeneity or power, for a given single heterogeneous
component. This process was repeated holding the treatment
effect for cardiovascular death and MI the same, and varying this
for cardiac arrest. Lastly, the treatment effect for cardiovascular
death and cardiac arrest were kept constant while the treatment
effect for MI was varied.
Data were simulated and analyzed in R for Unix version 2.11.1
[28]. This was calculated over 1500 iterations per condition. Based
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POISE[14], 1500 iterations should allow us to estimate an
interaction term within a level of accuracy of 0.01 to 0.02, using
a two-tailed type I error rate of 0.05 [29]. Example R code for this
simulation is included in appendix S1.
Finally we demonstrated the use of a composite outcome
heterogeneity test by re-analyzing the POISE [14] data using a
marginal time-to-event model [23,24,27]. The overall heteroge-
neity test compared the effect of peri-operative beta-blockers vs.
placebo on cardiovascular death compared to myocardial
infarction, and non-fatal cardiac arrest compared to myocardial
infarction. Contrasts were fit comparing the effect of beta-blockers
for among the three outcome types. Further to this, we
summarized the degree of heterogeneity using an ‘‘I
2 type’’ test,
taking the difference of chi-square value for the composite
treatment heterogeneity test from its degrees of freedom as a
percentage of the chi-square value itself. This test is typically used
to quantify the degree of heterogeneity across different studies in
meta-analyses [30]. The test can be interpreted as the percentage
of total variation due to true differences (i.e. not chance) in
treatment effects across the components of the composite outcome.
Results
Figure 2 displays the power to detect treatment heterogeneity
within the composite outcome as a function of the treatment effect
for each outcome in the composite for our simulated trial. As
expected, for all three outcomes the power to detect treatment
heterogeneity within the composite outcome increased as a single
outcomes’ hazard ratio become more different from the remaining
two. There was 50% power to detect that MI had a hazard ratio of
1.03 and 80% power to detect a hazard ratio of 1.18. There was
50% and 80% power to detect that cardiovascular death has larger
hazard ratios of 1.06 and 1.22, respectively. Lastly, this simulated
trial had the lowest power to detect that cardiac arrest had a
different treatment effect compared to the other two outcomes,
with 50% power to detect a hazard ratio of 1.25 and 80% power
for a hazard ratio of 1.51.
Therefore, with this simulated study design there is some power
to detect one outcome within the composite to be in the neutral to
harmful range, depending on which outcome. This design would
have little chance of demonstrating differences between the
outcomes if all showed varying degrees of benefit due to treatment.
The amount of power for composite treatment heterogeneity did
depend on the standard error of the interaction term being
manipulated, with power being greatest for a comparison of
cardiovascular death versus MI (and reverse) as compared to
cardiac arrest versus MI (since s
2
b4,s
2
b5).
For the actual POISE trial results [14] the interaction of
treatment with outcome type was statistically significant, indicating
composite outcome heterogeneity (p=0.0072) (see table 2).
Contrasts across the composite components provide evidence for
a difference in treatment effect for cardiovascular death when
compared to myocardial infarction (p=0.0024), but no statistically
significant difference for cardiac arrest compared to myocardial
infarction, although there were relatively few cardiac arrests. For
this effect, the value of I
2=79.8 (95% CI: 36.3% to 93.6%),
indicating a large amount of heterogeneity [30]. These results re-
enforce the treatment pattern observed for the individual
components in figure 1.
Discussion
Trialists may find this new test useful in planning and analyzing
trialsthatusecompositeoutcomes.Atthedesignstage,trialistscould
explorethedegreeoftreatmentdifferencesthatcouldbedetectedfor
Table 1. Estimated robust covariance matrix S.
ˆ S = s
2
b1 sb1b2 sb1b3 sb1b4 sb1b5 = 0.010 0.003 0.003 20.008 20.007
sb1b2 s
2
b2 sb2b3 sb2b4 sb2b5 0.003 0.019 0.006 20.019 20.006
sb1b3 sb2b3 s
2
b3 sb3b4 sb3b5 0.003 0.006 0.054 20.006 20.054
sb1b4 sb2b4 sb3b4 s
2
b4 sb4b5 20.008 20.019 20.006 0.036 0.009
sb1b5 sb2b5 sb3b5 sb4b5 s
2
b5 20.007 20.006 20.054 0.009 0.104
doi:10.1371/journal.pone.0034785.t001
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Figure 2. Power to detect treatment heterogeneity for each
individual outcome within the composite outcome. Power to
detect that the treatment hazard ratio for outcome is different from the
remaining two outcomes, as it hazard ratio varied from 0.70 to 2.0
(horizontal axis). The hazard ratios for the other two outcomes are kept
constant at 0.70. Each outcome is represented by a different power
curve.
doi:10.1371/journal.pone.0034785.g002
Table 2. Composite outcome treatment heterogeneity test
results for the POISE trial .
Heterogeneity Test for
Treatment Effect p-value
Overall Composite 0.0072
Cardiovascular death vs. MI 0.0024
Cardiac arrest vs. MI 0.1976
Results of heterogeneity tests for the actual trial data.
doi:10.1371/journal.pone.0034785.t002
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and covariances. Such power calculations are possible, even for
complex composite heterogeneity patterns across multiple individ-
ual outcomes. This information may be considered in selecting the
final trial design and sample size. If trial sample size cannot be
altered based on this knowledge, then at least trialists can be
informed of the degree of composite treatment heterogeneity they
can detect with their current design. If a trial has very little power to
detect a statistically different treatment effect for one outcome, for
example non-fatal cardiac arrest in POISE[14], then this may
inform and change our discussion of trial results.
A composite outcome heterogeneity test may be an additional
piece of information that readers can consider when interpreting a
trial results for a composite outcome. Such a test could help us
distinguish real differences in outcome treatment effects within a
composite from mere random variation. When readers examine
treatment estimates on the individual outcomes in the composite, a
heterogeneity test may discourage them from interpreting minor
variations in treatment estimates as real differences between
outcomes. Use of such a test itself may reinforce the play of chance
on individual outcome results within a trial, as was done for
subgroup analysis [11,12,31].
It would be beneficial to include discussion of possible treatment
differences within a composite outcome in the trial pre-specified
statistical analysis. Any comprehensive statistical analysis plan
should define the assumptions of the models that will be used and
suggest alternative models to be substituted if these assumptions are
not met. As in any statistical analysis, the appropriate model
assumptions must be examined prior to estimation of the treatment
effect, to avoid a biased treatment estimate. For example, when
using a linear regression the analyst must check for normality and
independence of the error terms [32]. When using a proportional
hazards model, the assumption of proportional hazards must be
examined prior to model fitting [26]. Similarly, for a model
analyzing a compositeoutcome,formedbased onthe assumption of
homogeneity of treatment effect across its components, researchers
wouldnotwanttoemphasizetheestimatedtreatmenteffectfromthe
compositeoutcomeifitwerenotareasonableestimateoftheoverall
effect.Guidancetodistinguishrandomvariationintreatmenteffects
from important outcome differences may help in this decision. If
there is evidence of composite heterogeneity, it may be unwise to
proceed with the typically model. The composite outcome result
could be presented along side with the treatment heterogeneity test
result and possible I
2 value, to clarify it interpretation. This may be
followed by a discussion of evidence for and against the initial
treatment homogeneity assumption. This observed effect may lead
to further exploration ofthe mechanisms of action for the treatment
being investigated. It could also guide the selection composite
outcomes for future trials.
Moreresearchisneededtoinvestigatetestsofcompositeoutcome
treatment heterogeneity for a variety of outcome types and RCT
designs. Our power calculations have assumed that the estimates of
bothoutcomeratesandtheassociationsbetweensurvivaltimesfrom
a past trial accurately estimate these for future trials. One could also
dosensitivityanalysestoseehowthepowerforthistestwouldchange
ifthesewereover-estimatesorunder-estimates.Itwouldbehelpfulif
published studies included information about the association or
correlation between the components of commonly used composite
outcomes, in addition to the composite outcome event rate itself.
Thereisalsomerittostudyingpowertodetecttreatmentdifferences
between individual outcomes within a composite when this effect of
treatmentisnotconstantovertime.Treatmentsthatmayshowearly
benefit but later harm would likely require incorporating time into
the heterogeneity test, forming outcome type by treatment by time
interaction term, but further research would be needed to explore
this scenario. Finally, we have applied the methods described to a
single RCT. POISE [14] is only one example where a composite
outcome heterogeneity test may have assisted in interpretation of
trial results, and there may be other trials where such a test may be
useful as well. This limits our inference and there is a need to apply
these methods to more trials to provide greater insight about the
patterns of treatment heterogeneity that commonly occurs in
composite outcomes and the broader applicability of our proposed
method.
Some may view the disadvantages of composite outcomes as
outweighing their advantages. Our perspective is that although the
disadvantages are real, composite outcomes will remain a reality
for most RCTs. In fact, most outcomes that appear as single
outcomes are composites of heterogeneous events. For example,
the single primary outcome of stroke will usually be a composite of
major and minor strokes or different types of stroke (e.g. intra-
cerebral bleed, cerebral infarction, etc.) that occur at different
frequencies and that may differ in their prognostic importance to
patients. Even total mortality is a composite of different types of
deaths, each of which may vary in response to a treatment. Despite
the limitations of composite endpoints, the beneficial aspects
related to sample size, cost, and clinical relevance make a
persuasive argument for the continued use of composite outcomes
in future trials. Therefore there is a need for guidance on how to
determine when a composite outcome may not be appropriate to
use and interpret for an individual RCT.
It is clear that a new direction is needed for the analysis of
composite outcomes. The methods outlined in this manuscript
provide a possible framework for approaching this problem and
may help us to use and interpret composite outcomes more wisely.
Supporting Information
Appendix S1 R code to calculate power composite
outcome heterogeneity test. The following will calculate the
power to detect composite outcome treatment heterogeneity if
treatment does not change cardiovascular death (b4=0 or hazard
ratio=1.0) and both MI and non-fatal cardiac arrest have a
treatment hazard ratio=0.7 (interaction term b5=0): CO-
power(1500,4100,20.35667,21.43508,22.35138,0.35667,0).
The following will calculate the power to detect composite
outcome treatment heterogeneity if treatment does not change
non-fatal cardiac arrest (b5=0 or hazard ratio=1.0) and both MI
and cardiovascular death have a treatment hazard ratio=0.7
(interaction term b4=0): COpower(1500,4100,20.35667,
21.43508,22.35138,0,0.35667). The following will calculate the
power to detect composite outcome treatment heterogeneity if
treatment does not change MI (b1=0 or hazard ratio=1.0) and
both non-fatal cardiac arrest and cardiovascular death have a
treatment hazard ratio=0.7 (interaction terms b4=b5): CO-
power(1500,4100,0,21.43508,22.35138,20.35667,20.35667).
(DOC)
Author Contributions
Conceived and designed the experiments: JP PD SY. Performed the
experiments: JP PD SY. Analyzed the data: JP. Wrote the paper: JP LT PD
SY.
Designing Clinical Trials with Composite Outcomes
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34785References
1. DeMets D, Califf R (2002) Lessons learned from recent cardiovascular clinical
trials: Part I. Circulation 106: 746–751.
2. Ferreira-Gonzalez I, Busse J, Heels-Ansdell D, Montori V, Akl E, et al. (2007)
Problems with use of composite end points in cardiovascular trials: Systematic
review of randomized controlled trials. British Medical Journal.
3. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C (2003) Composite
outcomes in randomized trials: Greater precision but with greater uncertainty?
Journal of the American Medical Association 289: 2254–2259.
4. Montori V, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse J, Pacheco-
Huergo et al (2005) Validity of composite outcomes in clinical trials. British
Medical Journal 330: 594–596.
5. Montori V, Busse J, Permanyer-Miralda G, Ferreira-Gonzalez I, Guyatt G
(2005) How should clinicians interpret results reflecting the effect of an
intervention on composite endpoints: Should I dump this lump? ACP Journal
Club 143: A8–A9.
6. Moye, LA (2003) Multiple analyses in clinical trials. New York: Springer.
7. Neaton J, Gray G, Zuckerman B, Konstam M (2005) Key issues in end point
selection from heart failure trials: Composite end points. Journal of Cardiac
Failure 11: 567–575.
8. Huque M, Sankoh A (1997) A reviewer’s perspective on multiple endpoint issues
in clinical trials. Journal of Biopharmaceutical Statistics 7: 545–564.
9. Chi G (2005) Some issues with composite endpoints. Fundamental & Clinical
Pharmacology 19: 609–619.
10. Sankoh A, D’Agostino Sr R, Huque M (2003) Efficacy endpoint selection and
multiplicity adjustment methods in clinical trials with inherent multiple endpoint
issues. Statistics in Medicine 22: 3133–3150.
11. Pocock S, Assmann S, Enos L, Kasten L (2002) Subgroup analysis, covariate
adjustment and baseline comparisons in clinical trial reporting: current practice
and problems. Statistics in Medicine 21: 2917–2930.
12. Yusuf S, Wittes J, Probstfield J, Tyroler H (1991) Analysis and interpretation of
treatment effects in subgroups of patients in randomized clinical trials. Journal of
the American Medical Association 93–98.
13. Petitti D (2001) Approaches to heterogeneity in meta-analysis. Statistics in
Medicine 20: 3625–3633.
14. Devereaux P, Yang H, Yusuf S, Guyatt G, Leslie K, et al. (2008) Effects of
extended-release metoprolol succinate in patients undergoing non-cardiac
surgery (POISE trial): a randomised controlled trial. The Lancet 371:
1839–1847.
15. McCullagh, P, Nelder, JA (1989) Generalized Linear Models. London:
Chapman and Hall.
16. Liang K, Zeger S (1986) Longitudinal data analysis using generalized linear
models. Biometrika 73: 13–22.
17. Tilley B, Marler J, Geller N, Lu M, Legler J, et al. (1996) for the National
Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial
Study Group. Use of a global test for multiple outcomes in stroke trials with
application to the National Institute of Neurological Disorders and Stroke t-PA
Trial. Stroke 27: 2136–2142.
18. Zeger S, Liang K (1992) An overview of methods for the analysis of longitudinal
data. Statistics in Medicine 11: 1825–1839.
19. Pogue J, Thabane L, Devereaux P, Yusuf S (2010) Testing for heterogeneity
among the components of a binary composite outcome in a clinical trial. BMC
Medical Research Methodology 10.
20. Donald A, Donner A (1987) Adjustment to the Mantel-Haenszel chi-squared
statistic and odds ratio estimator when the data are clustered. Statistics in
Medicine 6: 491–499.
21. Rao J, Scott A (1992) A simple method for the analysis of clustered binary data.
Biometrics 48: 577–585.
22. Duchateau L, Janssen, P (2008) The Frailty Model. New York: Springer Science.
23. Wei L, Lin D, Weissfeld L (1989) Regression analysis of multivariate incomplete
failure time data by modeling marginal distributions. Journal of the American
Statistical Association 84: 1065–1073.
24. Wei L, Glidden D (1997) An overview of statistical methods for multiple failure
time data in clinical trials. Statistics in Medicine 16: 833–839.
25. Pogue, J (2012) Testing for treatment heterogeneity between the individual
outcomes within a composite outcome [dissertation]. McMaster University.
26. Cox D (1972) Regression models and life-tables. Journal of the Royal Statistical
Society, Series B 34: 187–202.
27. Lin D, Wei L (1992) Linear regression analysis for multivariate failure time
observations. Journal of the American Statistical Association 87: 1091–1097.
28. R Development Core Team (2008) R A language and environment for statistical
computing., version 2.11.1 [computer program]. Vienna, Austria: R Foundation
for Statistical Computing.
29. Burton A, Altman D, Royston P, Holder R (2006) The design of simulation
studies in medical statistics. Statistics in Medicine 25: 4279–4292.
30. Higgins J, Thompson S, Deeks J, Altman D (2008) Measuring inconsistency in
meta-analyses. British Medical Journal 327: 557–560.
31. Assman S, Pocock S, Enos L, Kasten L (2000) Subgroup analysis and other
(mis)uses of baseline data in clinical trials. The Lancet 355: 1064–1069.
32. Montgomery, DC, Peck, EA (1982) Introduction to Linear Regression Analysis.
New York: John Wiley & Sons.
Designing Clinical Trials with Composite Outcomes
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34785